论文信息 - BRAF V600E inhibition in anaplastic thyroid cancer. - 字舞流文

BRAF V600E inhibition in anaplastic thyroid cancer.

A patient with rapidly progressive anaplastic thyroid cancer bearing the BRAF V600E mutation has a dramatic response to vemurafenib.

J. Glaspy | Parvin F Peddi | Parvin F. Peddi | M. Rosove

[1] C. von Kalle,et al. BRAF inhibition in refractory hairy-cell leukemia. , 2012, The New England journal of medicine.

[2] C. Nucera,et al. Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer. , 2012, Endocrinology.

[3] T. Takano,et al. BRAFV600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas , 2007, British Journal of Cancer.

[4] M. Nikiforova,et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. , 2003, The Journal of clinical endocrinology and metabolism.

[5] T. Eberlein,et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .